Aravive (FRA:VE11) Debt-to-Equity

: 1.43 (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

Aravive's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €1.99 Mil. Aravive's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.29 Mil. Aravive's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €1.59 Mil. Aravive's debt to equity for the quarter that ended in Sep. 2023 was 1.43.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aravive's Debt-to-Equity or its related term are showing as below:

FRA:VE11' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.15 Med: 0.15 Max: 1.43
Current: 1.43

During the past 11 years, the highest Debt-to-Equity Ratio of Aravive was 1.43. The lowest was -0.15. And the median was 0.15.

FRA:VE11's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs FRA:VE11: 1.43

Aravive Debt-to-Equity Historical Data

The historical data trend for Aravive's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

0.12

0.15

0.18

0.15

0.38

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity																0.31	0.38	-0.09	-0.15	1.43

Competitive Comparison

For the Biotechnology subindustry, Aravive's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aravive Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Aravive's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aravive's Debt-to-Equity falls into.

Aravive Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aravive's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.072	+	1.777)	/	10.06
	=	0.38

Aravive's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.987	+	0.287)	/	1.594
	=	1.43

Aravive (FRA:VE11) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aravive Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Aravive's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (FRA:VE11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (FRA:VE11) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ARAV:USA

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (FRA:VE11) Headlines

No Headlines